In 2024, the company initiated human trials for its brain implant after resolving safety issues highlighted by the US Food and Drug Administration, which had previously declined its application in 2022.
1 Min Read
Neuralink has not yet responded to a Reuters inquiry for further details.
The implant aims to assist individuals with conditions like spinal cord injuries. The first patient has utilized it to play video games, surf the internet, post on social media, and manipulate a laptop cursor.
Read Also: ITC shares fall to a three-year low; Analysts downgrade, slash price targets on excise duty hike
The company began human trials of its brain implant in 2024 after addressing safety concerns raised by the US Food and Drug Administration, which had initially rejected its application in 2022.
Neuralink indicated in September that 12 individuals globally with severe paralysis have received its implants, enabling them to control digital and physical tools via thought. They also secured $650 million in a funding round in June.
